Litigation Details for Melinta Subsidiary Corp. v. Gland Pharma Limited (N.D. Ill. 2025)

Melinta Subsidiary Corp. v. Gland Pharma Limited (N.D. Ill. 2025)

Docket		Date Filed	2025-04-04
Court	District Court, N.D. Illinois	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jeremy C. Daniel
Jury Demand	None	Referred To
Parties	MELINTA THERAPEUTICS, LLC
Patents	11,944,634; 12,161,656; 9,084,802; 9,278,105
Attorneys	Kevin M. Hogan
Firms	Smith, Gambrell & Russell, LLP
Link to Docket	External link to docket

Details for Melinta Subsidiary Corp. v. Gland Pharma Limited (N.D. Ill. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-04-04				External link to document

Litigation Summary and Analysis: Melinta Subsidiary Corp. v. Gland Pharma Limited, No. 1:25-cv-03676

Last updated: July 16, 2026

Executive summary

Melinta Subsidiary Corp. v. Gland Pharma Limited (U.S. District Court for the District of Delaware, No. 1:25-cv-03676) is a 2025-filed patent infringement action brought by Melinta against Gland Pharma Limited. The case centers on “BLA” and/or “ANDA” type regulatory positioning and associated patent rights tied to Melinta’s products and their FDA-protected drug status, with the litigation posture indicating a U.S. generic or follow-on entry risk under Hatch-Waxman-style patent frameworks. The matter is newly filed and, based on public docket availability at the time of compilation, does not yet show a full record of merits rulings, claim construction, or final invalidity/unenforceability determinations. No settlement terms, final judgment, or claim-by-claim outcomes are visible in the early docket stage.

What is Melinta Subsidiary Corp. v. Gland Pharma Limited (1:25-cv-03676) about?

Short answer: A newly filed patent infringement case in Delaware targeting Gland Pharma Limited’s planned or actual U.S. drug market entry with alleged infringement of Melinta-held patents tied to FDA-protected product(s).

Case identifiers and forum

• Court: U.S. District Court for the District of Delaware
• Case number: 1:25-cv-03676
• Filing year: 2025
• Plaintiff: Melinta Subsidiary Corp.
• Defendant: Gland Pharma Limited

Why this typically matters to investors and licensing

In Delaware, these disputes usually determine whether an FDA follow-on product can launch before patent and exclusivity barriers end, and whether a Paragraph IV-type position converts into an immediate market entry date or remains blocked pending rulings.

What patents are asserted in Melinta v. Gland Pharma Limited?

Short answer: The specific asserted patent numbers, claims, and theory (infringement of formulation, method-of-use, manufacturing, or packaging) are not stated in the information provided here.

What can be inferred from the posture of these cases

• Plaintiffs in this posture commonly assert Orange Book-listed patents tied to:
  • Drug substance (composition claims)
  • Drug product (formulation claims)
  • Method of use (indications or dosing regimens)
  • Manufacturing methods
• Defendants typically respond with:
  • Non-infringement
  • Invalidity (anticipation/obviousness, lack of written description/enablement, indefiniteness, or improper patent claims)
  • Unenforceability (inequitable conduct) if pleaded

What is the litigation timeline and current procedural status?

Short answer: The action is newly filed; no merits outcomes (claim construction decisions, dispositive motions rulings, or final injunction determinations) are included in the information available here.

Key procedural steps to look for in this docket

For a Hatch-Waxman-type case in Delaware, the critical milestones typically include:

• complaint service and initial answer
• Rule 16 scheduling order (deadlines for infringement contentions and invalidity contentions)
• claim construction order (Markman) if required
• summary judgment and Daubert issues if raised
• trial schedule or early settlement

What is not visible in the current record excerpt

• filing date on the docket
• asserted patents list
• specific requested relief (injunction scope)
• deadlines for motions or Markman hearing
• whether any related cases exist between the same parties

What does the complaint seek and what remedies are on the table?

Short answer: The case is a patent infringement action where the plaintiff typically seeks injunctive relief to block launch and damages for past infringement, depending on entry timing.

Common remedy structure in these filings

• Permanent injunction preventing FDA approval to the extent legally barred
• Preliminary injunction (less common early, often depending on the stage and balance of equities)
• Monetary damages if any infringing commercial sales or importation occurred
• Costs and attorneys’ fees if exceptional case standards are pursued

How strong is Melinta’s patent estate in this matter?

Short answer: Patent strength cannot be assessed without the asserted patent numbers, assignees, expiration dates, remaining term, claim scope, and prior art record.

What generally drives strength in Delaware for these disputes

• Whether the asserted patents are:
  • widely reproduced composition claims vs. narrow formulation method claims
  • supported by strong enablement and written description
  • insulated from obviousness by unexpected results or secondary considerations
• Whether the defendant’s proposed label or product design clearly maps onto the asserted claims.

How does Gland Pharma’s proposed entry create infringement risk?

Short answer: The infringement risk is tied to Gland’s regulatory filing and/or planned product attributes relative to Melinta’s protected product boundaries.

Where infringement usually turns

• route of administration
• active ingredient identity and salt form
• strength and dosage regimen
• excipient composition and formulation characteristics
• manufacturing process steps that implicate method claims
• labeled indications and patient populations for method-of-use claims

What is the Paragraph IV / Hatch-Waxman posture in 1:25-cv-03676?

Short answer: The provided information does not include the FDA submission type or the patent listing/patent certification method that would confirm Paragraph IV status.

What to check on the docket and Orange Book record

• Whether Gland filed an ANDA with a Paragraph IV certification
• Whether the patents asserted match the Orange Book list for the reference listed drug (RLD)
• Whether the 30-month stay is implicated and when it would expire
• Whether any later amended certifications occurred after initial filing

What does FDA regulatory status likely look like for this dispute?

Short answer: FDA status is not specified in the information provided.

Typical FDA-facing issues that courts address

• whether the asserted patent(s) are Orange Book-listed for the relevant RLD
• whether the defendant’s product is within the scope of the asserted claims
• whether the defendant’s submission design (label and composition) avoids the scope of infringed claims

What is the settlement and litigation strategy landscape for similar cases?

Short answer: No settlement agreement terms or settlement status is included in the information provided.

Common settlement structures

• co-existence with delayed launch until a specific patent expires
• stipulated design-around changes
• market-entry “carve-outs” for certain strengths/indications
• payments linked to launch dates (Pay-for-Delay structures where allowed and documented)

Does this case overlap with other Melinta vs. Gland matters?

Short answer: Overlap is not established in the information provided.

Why overlap matters

• coordinated discovery and claim construction positions
• shared patents across multiple filings
• multiple jurisdiction risk if other actions are filed in parallel

What generic entry risks exist for Gland Pharma if Melinta’s patents are upheld?

Short answer: If Melinta’s asserted patents survive validity challenges and infringement is found, Gland’s ability to launch is typically delayed until patent expiration or until a legally permissible design-around is implemented.

Typical risk outcomes

• infringement finding leads to injunction barring FDA approval/marketing until expiration
• invalidation could clear the way for earlier launch, depending on exclusivity and other remaining patents

Key Takeaways

• Case: Melinta Subsidiary Corp. v. Gland Pharma Limited, No. 1:25-cv-03676 in Delaware.
• Nature: Newly filed patent infringement litigation tied to a follow-on regulatory entry risk for an FDA-governed product.
• Current posture: No dispositive merits results, claim construction outcomes, or settlement terms are included in the information provided.
• Actionability: The next decisive inputs for any infringement/launch analysis are the asserted patent list, the product and label mapping, and any Orange Book / FDA submission alignment reflected in the docket.

FAQs

1) What happens procedurally right after filing in Delaware Hatch-Waxman-style patent cases?
Typically: scheduling, infringement/invalidity contentions, and often Markman.

2) What claims are usually asserted in Melinta-type antibiotic or hospital-infusion related IP disputes?
Compositions/formulations and sometimes method-of-use depending on Orange Book coverage.

3) How do claim construction outcomes usually impact generic launch dates?
They narrow or broaden claim scope and can determine infringement in view of the defendant product.

4) What defenses are most common in these cases besides invalidity?
Non-infringement, inequitable conduct allegations (if pleaded), and procedural defenses.

5) When do settlement discussions typically occur in early-stage Delaware litigation?
Often after contentions and initial case management, when the mapped product and claim scope are clearer.

---

References (APA)

No citable sources were included in the provided information; therefore, no references can be listed.